221 related articles for article (PubMed ID: 20186149)
1. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice.
Shiota A; Yamamoto K; Ohishi M; Tatara Y; Ohnishi M; Maekawa Y; Iwamoto Y; Takeda M; Rakugi H
Hypertens Res; 2010 Apr; 33(4):298-307. PubMed ID: 20186149
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes.
Tikellis C; Brown R; Head GA; Cooper ME; Thomas MC
Am J Physiol Renal Physiol; 2014 Apr; 306(7):F773-80. PubMed ID: 24477684
[TBL] [Abstract][Full Text] [Related]
3. Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes.
Tikellis C; Pickering R; Tsorotes D; Du XJ; Kiriazis H; Nguyen-Huu TP; Head GA; Cooper ME; Thomas MC
Clin Sci (Lond); 2012 Oct; 123(8):519-29. PubMed ID: 22616805
[TBL] [Abstract][Full Text] [Related]
4. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.
Ye M; Wysocki J; William J; Soler MJ; Cokic I; Batlle D
J Am Soc Nephrol; 2006 Nov; 17(11):3067-75. PubMed ID: 17021266
[TBL] [Abstract][Full Text] [Related]
5. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.
Mima A; Arai H; Matsubara T; Abe H; Nagai K; Tamura Y; Torikoshi K; Araki M; Kanamori H; Takahashi T; Tominaga T; Matsuura M; Iehara N; Fukatsu A; Kita T; Doi T
Diabetes; 2008 Jun; 57(6):1712-22. PubMed ID: 18285555
[TBL] [Abstract][Full Text] [Related]
6. Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice.
Lakshmanan AP; Thandavarayan RA; Watanabe K; Sari FR; Meilei H; Giridharan VV; Sukumaran V; Soetikno V; Arumugam S; Suzuki K; Kodama M
Mol Cell Endocrinol; 2012 Jan; 348(1):104-11. PubMed ID: 21827824
[TBL] [Abstract][Full Text] [Related]
7. Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy.
Wang G; Lai FM; Lai KB; Chow KM; Kwan CH; Li KT; Szeto CC
Am J Nephrol; 2009; 29(6):524-31. PubMed ID: 19077419
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.
Wysocki J; Ye M; Khattab AM; Fogo A; Martin A; David NV; Kanwar Y; Osborn M; Batlle D
Kidney Int; 2017 Jun; 91(6):1336-1346. PubMed ID: 27927599
[TBL] [Abstract][Full Text] [Related]
9. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury.
Wong DW; Oudit GY; Reich H; Kassiri Z; Zhou J; Liu QC; Backx PH; Penninger JM; Herzenberg AM; Scholey JW
Am J Pathol; 2007 Aug; 171(2):438-51. PubMed ID: 17600118
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
Motawi TK; El-Maraghy SA; Senousy MA
J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
[TBL] [Abstract][Full Text] [Related]
11. Chronic diabetic nephropathy: role of inducible nitric oxide synthase.
Trachtman H; Futterweit S; Pine E; Mann J; Valderrama E
Pediatr Nephrol; 2002 Jan; 17(1):20-9. PubMed ID: 11793130
[TBL] [Abstract][Full Text] [Related]
12. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice.
Lassila M; Jandeleit-Dahm K; Seah KK; Smith CM; Calkin AC; Allen TJ; Cooper ME
J Am Soc Nephrol; 2005 Feb; 16(2):363-73. PubMed ID: 15625075
[TBL] [Abstract][Full Text] [Related]
13. Role of angiotensin-converting enzyme (ACE and ACE2) imbalance on tourniquet-induced remote kidney injury in a mouse hindlimb ischemia-reperfusion model.
Yang XH; Wang YH; Wang JJ; Liu YC; Deng W; Qin C; Gao JL; Zhang LY
Peptides; 2012 Jul; 36(1):60-70. PubMed ID: 22580272
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme 2 and the kidney.
Soler MJ; Wysocki J; Batlle D
Exp Physiol; 2008 May; 93(5):549-56. PubMed ID: 18223023
[TBL] [Abstract][Full Text] [Related]
16. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes.
Tikellis C; Bialkowski K; Pete J; Sheehy K; Su Q; Johnston C; Cooper ME; Thomas MC
Diabetes; 2008 Apr; 57(4):1018-25. PubMed ID: 18235039
[TBL] [Abstract][Full Text] [Related]
17. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice.
Soler MJ; Wysocki J; Ye M; Lloveras J; Kanwar Y; Batlle D
Kidney Int; 2007 Sep; 72(5):614-23. PubMed ID: 17579661
[TBL] [Abstract][Full Text] [Related]
18. Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling.
Jin HY; Chen LJ; Zhang ZZ; Xu YL; Song B; Xu R; Oudit GY; Gao PJ; Zhu DL; Zhong JC
J Transl Med; 2015 Aug; 13():255. PubMed ID: 26245758
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme activity in retinas of streptozotocin-induced and Zucker diabetic rats. The effect of angiotensin II on Na+,K(+)-ATPase activity.
Ottlecz A; Bensaoula T; Eichberg J; Peterson RG
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2157-64. PubMed ID: 8843902
[TBL] [Abstract][Full Text] [Related]
20. ACE and ACE2 activity in diabetic mice.
Wysocki J; Ye M; Soler MJ; Gurley SB; Xiao HD; Bernstein KE; Coffman TM; Chen S; Batlle D
Diabetes; 2006 Jul; 55(7):2132-9. PubMed ID: 16804085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
